Fifteen million Americans who take a class of drugs to treat type 2 diabetes are at risk for developing bladder cancer, according to a new study published this month in the Journal of the National Cancer Institute. As much as 20 percent of the drugs prescribed to diabetics in the United States are thiazolidinediones, or TZDs. Drugs in this class include Avandia (rosiglitazone), Actos (pioglitazone) and Rezulin (troglitazone). In 2008, the Food and Drug Administration (FDA) withdrew Rezulin from the market due to an increased incidence of drug-induced hepatitis. In 2010, the FDA severely restricted the use of Avandia after ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.